Bit Index AI  | Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


Close [ X ]
Copy this code to embed & stream this video on your website
Copy this URL to share or create a link back to this video
Prof. Dr. Olaf G. Wilhelm
Chief Executive Officer
WILEX AG - Research and development of smallmolecule drugs for autoimmune diseases and cancer
The therapeutic agent RENCAREX® (INN: Girentuximab) is a targeted antibody for the treatment of solid tumours. The antibody Girentuximab binds to the CA IX antigen expressed on the tumour cells, thereby triggering an immune reaction called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this mechanism, effector cells, e.g. NK (natural killer) cells, of the immune system are activated to kill the tumour cells.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
WILEX AG, Guiding targeted therapies through diagnostics
sales, Deals, Alliances, Oncology-focused biopharmaceutical, clinical and commercial milestones, combination of therapeutics and diagnostics, Products Technologies , At a glance
portfolio, partners, REDECTANE®, RENCAREX®, MESUPRON®, WX-554, WX-037, Antibodies, ADC Platform , Broad portfolio and strong partners
commercialisation strategy, Therapeutics, Diagnostics, Research, Royalties, Licensing, Revenues, Licensing, income, Positioning in three segments
personalised cancer treatment, CA IX, therapeutics, diagnostics, Oncogene Science , WILEX Group's combined offering
Carbonic Anhydrase IX (CAIX), HIF-1, biomarker, hypoxia, What is Carbonic Anhydrase IX (CAIX) and what does it do?
Diagnostic imaging , Diagnostic imaging
REDECTANE®, renal cell cancer (ccRCC), , REDECTANE (R): Diagnosis of clear cell renal cell cancer (ccRCC)
Girentuximab (cG250), Nijmegen, MSKCC/LICR, SPA approved by FDA , Development of the REDECTANE (R) concept
metastases, metastasis, REDECTANE (R) detects primary tumour and distant metastases
REDECTANE(R) detects also small tumours: T1a (1.7cm) ccRCC , REDECTANE(R) detects also small tumours: T1a (1.7cm) ccRCC
Final study results, REDECTANE (R): Final study results
In-vitro diagnostic , In-vitro diagnostic
Univariate analysis of biomarker in trastuzumab-treated MBC, Univariate Analysis, HER2, TIMP-1, uPA, Endoglin, CAIX, VEGF, Serum Biomarker, (PFS) p-value, (OS) p-value , Univariate analysis of biomarker in trastuzumab-treated MBC
pretreatment serum CAIX, Probability, Serum CAIX , Elevated pretreatment serum CAIX predicts reduced survival
Multivariate analysis, biomarker in trastuzumab-treated MBC, Progression-Free Survival (PFS), Conclusions , Multivariate analysis of biomarker in trastuzumab-treated MBC
oncological biomarker, personalised medicine, kidney, cervix, lung, bladder, colon and head & neck , CAIX: important oncological biomarker in the development of personalised medicine
Forward looking statements , Forward Looking Statements